Compare CNOBP & YDESW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CNOBP | YDESW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 1995 | 2024 |
| Metric | CNOBP | YDESW |
|---|---|---|
| Price | $25.25 | $0.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.9K | ★ 11.7K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.51 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.81 | $0.19 |
| 52 Week High | $25.51 | $2.40 |
| Indicator | CNOBP | YDESW |
|---|---|---|
| Relative Strength Index (RSI) | 50.93 | 62.05 |
| Support Level | $25.15 | $0.36 |
| Resistance Level | $25.48 | $0.58 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 40.10 | 76.73 |
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets, and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental, and consumer wages.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.